**Introduction**

Phototherapy is an effective treatment method for many skin diseases. The most important chronic side effect of phototherapy is carcinogenesis. According to the information available, although the carcinogenetic effects of narrowband ultraviolet B (NBUVB) treatment seems more moderate when compared to other forms of phototherapy, its long-term reliability is not known exactly [1].

Dermoscopy is among the optical techniques with higher efficacy in the earlier diagnosis of skin cancer compared to naked-eye examination [2]. For this reason, total body examinations, both clinical and dermoscopic, are being performed in many centers before and during phototherapy.
UV light can cause clinical, histopathologic and dermoscopic changes in melanocytic nevi (MN) [3-5]. The dermoscopic changes observed in MN after NBUVB or ultraviolet A1 (UVA1) exposure did not occur in MN covered with opaque tape or sunscreen cream (SSc). In the direction of these findings, it was suggested that the dermoscopic changes induced by UVA1 and ultraviolet B (UVB) can be prevented successfully with either opaque tape or highly protective factor SSc; however, no significant histologic and immunohistochemical changes were detected in MN showing dermoscopic changes [6]. Although dermoscopic changes were recorded in a significantly few amount of covered MN during phototherapy sessions, they still occurred in a noteworthy part of the covered MN [5,7,9]. The Turkish Dermatology Society Phototherapy Guidelines advise covering big and atypical MN and premalignant lesions before phototherapy [9].

Based on the above findings, we covered half of the selected MN with opaque tape and SSc and the rest with only opaque tape during all phototherapy sessions in order to investigate whether the use of SSc in addition to opaque tape has an additive effect in preventing dermoscopic changes induced by UV exposure. We also evaluated the development of new MN during follow-up. As far as we know, our study is the first study searching dermoscopic changes in covered MN with both opaque tape and SSc and new MN development during phototherapy.

Materials and Methods

All patients with a variety of dermatologic diseases were referred to our phototherapy unit for NBUVB therapy between January 28, 2015 and July 25, 2016 were evaluated in terms of eligibility for the study. The patients who were older than 1 year old and had at least two MN >2 mm size located on body and/or proximal extremity without melanoma suspicion were invited to participate in the study. Exclusion criteria included personal or family history of melanoma or cutaneous malignant epithelial tumor, active infection, atypical mole syndrome, active or previous history of systemic inflammatory or neoplastic disease, immunosuppressive medication, phototherapy history, and artificial UV exposure. MN located on sun-exposed body parts such as the head, neck, and distal extremities were not taken into consideration.

Every study participant signed an Informed Consent Form. Phototherapy was given using a Waldman UV 7001K (TL-01) device equipped with F85/100W-01 (TL01) Philips fluorescent tubes. At least two MN sized >2 mm were selected randomly in each patient. Half of the selected MN in each patient were covered with opaque tape after SSc application SSc(+), and the rest were covered only with opaque tape—without SSc application SSc(-). SSc was applied approximately 20 minutes before the opaque tape was applied. SPF 50 + SSc containing organic and inorganic filters against UVA-UVB (Solante; Buergli Pharma, Inc., Makati, Philippines) was used. Dermoscopic images of the selected MN were captured with a digital dermoscopy system at the beginning, at the end, and 3-6 months after the end of NBUVB therapy. At all follow-ups, total body mole mapping was performed with a fully automated body mole-mapping programme (Body Studio ATBM; FotoFinder Systems Inc, Columbia, MD, USA). Dermoscopic photographing, total body mole mapping, and arrangement of photographs were performed by one researcher (DÖK). The evaluation of the images was done by another researcher (NK) without knowing whether the lesion was SSc(+) or SSc(-). The MN that showed unexpected dermoscopic findings, such as decrease in size or loss of structure, were further evaluated by another researcher (IKK).

The data were analyzed with the SPSS Statistics 21 packet programme. Sustained variables were given as average a standard deviation, minimum – maximum assets and categorical variables for numbers and percentages. In order to compare the independent group discrepancies, the Mann-Whitney U test was used. The differences between categoric variables were examined with Chi-square test. For examination of risk factors, the logistic regression test was used.

Results

Of the 24 patients enrolled, a total of 165 MN were identified. Excluded from the study were 6 patients with 34 MN, who were lost to follow-up and 11 MN of included patients that had poor image quality. In sum, the study included 120 MN belonging to 18 patients (mean age: 44.7±14.2 years; 13 women).

The majority of patients were diagnosed with mycosis fungoides (n:5; 27.8%) and psoriasis (n:5; 27.8%); the remaining diagnoses were pruritus, granuloma annulare, pityriasis lichenoides chronica and perforating dermatoses. Fitzpatrick skin type 3 was the most common skin type (n:14; 77.8%). The mean cumulative treatment dose was 32.9±33.3 joule/cm² (range 1.53-100.14 joule/cm²). One patient received acitretin treatment in addition to phototherapy. Forty-two MN (18 SSc(+); 24 SSc (-)) were reexamined after a mean of 4.2±1.2 months (range: 3-6 months) after the end of NBUVB therapy. SSc(-) and SSc(+) groups constituted 68 (56.7%) and 52 (43.3%) patients, respectively.

The most frequently observed dermoscopic pattern was reticular pattern (n=50; 41%), followed by homogenous-reticular pattern (n=31; 25.8%), homogenous pattern (n=17; 14.2%), globular pattern (n=12; 10.0%), homogenous-globular pattern (n=8; 6.7%), and multicomponent pattern.
The ratio of SSc(+) MN that showed darkening pigmentation, darkening pigment network, increase in size, and decrease in the number of dot and/or globules were higher than SSc(-) MN (p>0.05) (Table 3). The dermoscopic changes 3-6 months after the end of NBUVB therapy compared to the beginning and the end of NBUVB therapy (n=2; 1.7%). Seventy percent of MN were located on the body, 25.8% on the arms, and 4.2% on the legs.

New MN development was not established during the study. Although the ratio of SSc(-) MN displaying dermoscopic changes was higher than SSc(+) MN at the end of NBUVB therapy compared to the beginning; the ratio of MN displaying dermoscopic changes was similar in both SSc(-) and SSc(+) groups 3-6 months after the end of NBUVB therapy compared to the beginning and the end of therapy (Table 1).

No differences in dermoscopic changes according to anatomic locations were detected between SSc(-) and SSc(+) groups (p>0.05).

Dermoscopic changes at the end of NBUVB therapy compared to the beginning: The ratios of SSc(-) MN that showed decrease in size and loss of structure were higher than SSc(+) MN (p=0.04 and p=0.026, respectively) (Figure 1). Failure to apply SSc over MN increased the ratio of decrease in size 4,681 times compared to MN applied with SSc (Exp(B): 4.681). The ratio of loss of structure was found to be increased 5.932 times in SSc(-) MN compared to SSc(+) MN (Exp(B):5.932). The mean exposed joules were comparable between the SSc(-) and SSc(+) MN showing decrease in size and loss of structure (p>0.05). More SSc(-) MN showed fading in pigmentation, fading in pigment network, new structure and/or color development, and increase in the number of dot and/or globules than SSc(+) MN; but not at a significant level (p>0.05) (Table 2).

The ratio of SSc(+) MN that showed darkening pigmentation, darkening pigment network, increase in size, and decrease in the number of dot and/or globules were higher than SSc(-) MN (p>0.05) (Table 3).

The dermoscopic changes 3-6 months after the end of NBUVB therapy compared to the beginning and the end of therapy: These analyses were performed in SSc(-) 24 MN and SSc(+) 18 MN that were reexamined after discontinuing therapy. Dermoscopic changes persisted in 7 MN [4 SSc (+); 3 SSc(-)] and new dermoscopic changes (late onset) emerged in 2 MN [2 SSc (+)] 3-6 months after the end of therapy. When the dermoscopic changes were considered separately, it was observed that most returned to their former state.

### Table 1. MN showing dermoscopic changes at the beginning, at the end, and 3-6 months after end of therapy

|                  | Beginning vs. end | End vs. 3-6 months after the end | End vs. 3-6 months after the end |
|------------------|-------------------|----------------------------------|----------------------------------|
| SSc(+); n(%)     | 19 (15.8%)        | 6 (14.2%)                        | 6 (14.2%)                        |
| SSc (-); n(%)    | 38 (31.6%)        | 6 (14.2%)                        | 3 (7.1%)                         |
| P value          | =0.035            | >0.05                            | >0.05                            |
| Total n(%)       | 57 (47.5%)        | 12 (28.5%)*                      | 9 (21.4%)*                       |

*These ratios were calculated within 42 MN that were reexamined after discontinuing therapy.

---

Figure 1. The nevi that showed fading in pigmentation and pigment network (B); fading in pigmentation together with decrease in size (D), and decrease in dots/globules together with increase in streaks and blue-gray color formation (F) at the end of therapy compared to the beginning (A, C and E, respectively). [Copyright: ©2018 Ok Kekeç et al.]
Discussion

Prevalence of MN changes according to age, genetic and environmental factors, and the number of MN, which are low in childhood can increase in time [10]. The most studied environmental factor in terms of relevance with MN development is UV light. An animal model demonstrated that UVB and UVA2 both induce MN development [11,12]. Epidemiological and twin studies revealed a relationship between the number of MN and the intermittent intense UV exposure; however, no relationship was established between daily UV exposure and MN number [13,14]. It was shown that as the experienced sunburn number and severity increase, new MN

or had a tendency to do so (Table 4, Figure 2). The dermoscopic changes and histopathologic results of excised MN are summarized in Table 5.

Before starting the study, it was calculated with 80% power that 95% confidence could be achieved if 49 MN would be included in each group (at least 98 MN) when power analysis had been performed, assuming the obtainable ratios would be 10% and 30%. When the results of the study were examined, power analysis was performed according to these results [for size decrease SSc(+) 9.6% vs SSc(-) 33.8%, and for structure loss SSc(+) 3.8% vs. SSc(-) 19.1%], and it was determined that the present study had 95% and 86% power, respectively, with 95% confidence.

**TABLE 2. More frequently observed dermoscopic changes in SSc(-) MN compared to SSc(+) MN at the beginning vs. end of NBUVB therapy**

| Parameter                        | SSc(+) n (%) | SSc(-) n (%) | P     |
|----------------------------------|--------------|--------------|-------|
| Decrease in size                 | 5 (9.6%)     | 23 (33.8%)   | =0.04 |
| Symmetric                        | 5            | 19           | >0.05 |
| Asymmetric                       | 0            | 4            |       |
| Loss of construction             | 2 (3.8%)     | 13 (19.1%)   | =0.026|
| Loss of pigment network          | 2            | 11           | >0.05 |
| Dots/globules                    | 0            | 1            |       |
| Branched streaks                 | 0            | 1            |       |
| Fading in pigmentation           | 19 (34.6%)   | 33 (47.1%)   | >0.05 |
| Symmetric-homogeneous            | 17           | 30           |       |
| Asymmetric                       | 0            | 2            | >0.05 |
| Central                          | 2            | 0            |       |
| Peripheral                       | 0            | 1            |       |
| Fading in pigment network        | 11 (21.2%)   | 19 (27.9%)   | >0.05 |
| Symmetric-homogeneous            | 11           | 19           | NA    |
| New structure formation          | 1 (1.9%)     | 6 (8.8%)     | >0.05 |
| Pigment network                  | 0            | 3            |       |
| Streaks                          | 0            | 1            |       |
| Dot-globul                       | 0            | 1            |       |
| White scar-like Depigmentation   | 1            | 1            | NA    |
| Structureless areas              | 1            | 0            |       |
| Ulcer                            | 1            | 0            |       |
| Chrysalis structures             | 1            | 0            |       |
| New color formation              | 1 (1.9%)     | 4 (5.9%)     | >0.05 |
| Blue                             | 0            | 1            | NA    |
| White                            | 1            | 1            | NA    |
| Blue-gray                        | 0            | 2            |       |
| Loss of color                    | 0 (0%)       | 1 (1.5%)     | NA    |
| Black                            | 0            | 1            | NA    |
| Increase of dots-globules        | 1 (1.9%)     | 1 (1.5%)     | NA    |

*NA= No Analysis

**The above given MN and the dermoscopic parameter numbers do not match, because more than one dermoscopic parameter was observed in one MN.
treatment [16,17] and even in 43.2% of covered MN during psoralen-ultraviolet A (PUVA) and NBUVB treatment [7]. We observed dermoscopic changes in most of the MN (65%) despite being covered with opaque tape in all and with SSc in half of them. Higher ratios that are found in our study may be related to the detailed dermoscopic evaluation parameters.

Lin et al recognized size changes in a larger proportion of the MN located on the abdominal region in comparison to the MN located on other body sites but noted no significant relation with skin type [16]. In our study, we did not detect any differences in dermoscopic changes between SSc(+) and SSc(-) MN groups according to anatomical location.

Kılınç Karaaslan et al observed increase in size in uncovered MN but not in opaque tape-covered MN at the end of development increases [15]. These findings explain that the nevogenic effect of UV is dose dependent and is distinctive in areas where environmental UV is much more intense. We did not observe new MN development in our study. It can be related to other factors, including that almost all our patients were dark phenotype, all were over 18 years old, and we had short-term follow-up. In addition, the ones who had severe sunburn history were excluded from the study, and during treatment the UV dosage were raised gradually. There are genetic factors that have not been identified, yet might have a role.

UV light can cause clinical, histopathologic and dermoscopic changes in MN by increasing melanin synthesis or inducing melanocyte proliferation [3-5]. Dermoscopic changes were reported in 27-50% of MN during NBUVB treatment [16,17] and even in 43.2% of covered MN during psoralen-ultraviolet A (PUVA) and NBUVB treatment [7]. We observed dermoscopic changes in most of the MN (65%) despite being covered with opaque tape in all and with SSc in half of them. Higher ratios that are found in our study may be related to the detailed dermoscopic evaluation parameters.

Lin et al recognized size changes in a larger proportion of the MN located on the abdominal region in comparison to the MN located on other body sites but noted no significant relation with skin type [16]. In our study, we did not detect any differences in dermoscopic changes between SSc(+) and SSc(-) MN groups according to anatomical location.

Kılınç Karaaslan et al observed increase in size in uncovered MN but not in opaque tape-covered MN at the end of

### TABLE 3. More frequently observed dermoscopic changes in SSc(+) MN compared to SSc(-) MN at the beginning vs. at the end of NBUVB therapy (n=120)

|                        | SSc(+); n (%) | SSc(-); n (%) | p*     |
|------------------------|---------------|---------------|--------|
| Increase in size       | 3 (5.8%)      | 3 (4.4%)      | p=0.05 |
| Symmetric              | 2             | 3             | NA     |
| Asymmetric             | 1             | 0             |        |
| Darkening in pigmentation | 4 (7.7%)     | 4 (5.9%)      | p=0.05 |
| Symmetric –homogenous  | 4             | 4             | NA     |
| Darkening in pigment network | 4 (7.7%)   | 2 (2.9%)      | p=0.05 |
| Symmetric –homogenous  | 4             | 2             | NA     |
| Decrease in the number of dots/globules | 4 (7.7%) | 4 (5.9%) | p=0.05 |

*NA= No Analysis

### TABLE 4. The course of dermoscopic changes 3-6 months after end of therapy*

|                        | Returned to the original state or tended to do so | Persisted or progressed | Late onset |
|------------------------|---------------------------------------------------|-------------------------|-----------|
| Increase in size       | 9.5 [4.6:6.4]                                    | 2.3 [2.3:0]             | 4.6 [2.3:2.3] |
| Decrease in size       | 21.4 [0:21.4]                                    | 4.6 [2.3:2.3]           | 2.3 [2.3:0] |
| Darkening in pigmentation | 9.5 [4.6:4.6]                                | 4.6 [4.6:0]             | 0         |
| Fading in pigmentation | 28.5 [6.9:21.4]                                  | 11.9 [4.6:6.9]          | 4.6 [4.6:0] |
| Darkening in pigment network | 9.5 [4.6:4.6]                               | 2.3 [2.3:0]             | 0         |
| Fading in pigment network | 16.6 [4.6:11.9]                               | 9.5 [2.3:6.9]           | 0         |
| New structure development | 6.9 [2.3:4.6]                                | 2.3 [0:2.3]             | 4.6 [2.3:2.3] |
| Loss of structure      | 14.2 [2.3:11.9]                                  | 2.3 [0:2.3]             | 2.3 [2.3:0] |
| Increase in the number of dots/globules | 0            | 2.3 [2.3:0]              | 2.3 [0:2.3] |
| Decrease in the number of dots/globules | 6.9 [2.3:4.6]                                | 0                       | 2.3 [2.3:0] |
| New color development  | 2.3 [0:2.3]                                     | 2.3 [2.3:0]             | 0         |
| Loss of color          | 2.3 [0:2.3]                                     | 0                       | 2.3 [0:2.3] |

* %total [%SSc(+): %SSc(-)]; these ratios were calculated within 42 MN that were reexamined after discontinuing therapy.
NBUVB, UVA1 and PUVA treatments for three months [17]. None of the above studies mention decrease in size in MN and it was not stated whether size decrease was taken into consideration.

Lin et al detected size change in 40% of MN during NBUVB treatment, and similar to our study, they evaluated MN size in terms of both decrease and increase. They

| Dermoscopic changes       | MN1 | MN2 | MN3 | MN4 |
|---------------------------|-----|-----|-----|-----|
| Structureless areas       | +   | -   | -   | -   |
| Ulcer                     | +   | -   | -   | -   |
| Chrysalis structures      | +   | -   | -   | -   |
| Streaks formation         | -   | -   | -   | +   |
| White scar-like depigmentation | +    | +   | -   | -   |
| Decrease in size          | -   | +   | +   | -   |
| Increase in size          | -   | -   | -   | +   |
| Fading in pigmentation    | -   | +   | +   | +   |
| Darkening in pigmentation | -   | -   | -   | +   |
| Fading in pigment network | -   | -   | +   | -   |
| Decrease in the number of dots/globules | -     | -   | -   | +   |
| Loss of pigment network   | -   | +   | -   | -   |
| Histopathologic diagnosis | Intradermal nevus | Junctional nevus | Junctional nevus | Dysplastic nevus |

Figure 2. Darkening in pigmentation and pigment network (B, E) and fading in pigmentation and pigment network (H) at the end of therapy compared to the beginning (A, D, G) in three MN. It is seen that dermoscopic changes showing tendency to return back (C), increasing (F) and persisting (I) 3-6 months after the end of therapy. [Copyright: ©2018 Ök Kekeç et al.]

TABLE 5. Dermoscopic changes in excised MN
observed size decrease and increase in 54% and 46% of MN that displayed size change, respectively [16].

Dobrosavljevic et al evaluated dermoscopic changes in MN of patients using and not using SSc 28 days after UV exposure for a minimum of 7 days. They did not detect any significant change in MN in terms of size increase between the two groups. However, 28 days after the end of UV exposure they observed that the fading in pigmentation in a large proportion of MN belonged to the group that was not using SSc compared to other group who was using SSc (61.9% vs. 20.5%, respectively) [18].

In our study, we detected size change in the 27.5% of MN, 84.8% of which showed decrease in size. The ratios of MN that showed size decrease and structure loss were statistically significantly higher in the SSc(-) group compared to the SSc(+). In addition, we also found the ratios of MN that showed fading in pigmentation network and in pigmentation were also higher in the SSc(-) group, although the difference did not reach a statistically significant level. We excised one of the MN that showed size decrease, fading in pigmentation, and pigmentation network, but no other dermoscopic change, and we did not detect atypical histopathologic findings. We thought that the above-mentioned dermoscopic findings might have emerged by induction of melanocyte apoptosis and blockage of melanin production from melanocytes by NBUVB [19,20]. According to our findings, it can be speculated that SSc application in combination with opaque tape may hinder the triggering effects of NBUVB over MN involution.

Hofmann–Wellenhof et al detected significant darkening in brown color and total irregularity generation in uncovered MN during UVB treatment but no significant dermoscopic changes in those covered by opaque tape. However, when considering MN covered and uncovered with opaque tape together, they recognized that MN showed significantly more “total irregularity,” darker “brown color,” and increase in brown globules and pigment network width at the end of UVB treatment compared to the beginning. In all, they thought these changes may depend on the systemic effects of UV radiation on MN [3]. The emergence of dermoscopic changes in the majority of MN during our study, despite being covered with opaque type, supports the systemic effects of UV on MN.

Kılınç Karaaslan et al established that the majority of dermoscopic changes arising after NBUVB and PUVA treatments were reversible [8]. Lin et al observed that while enlarged MN after NBUVB treatment tended to revert to pretreatment size 3 months after the cessation of therapy, the trend for MN showing size decrease was for continued size reduction [16].

The majority of dermoscopic changes occured in our study showed a tendency to return to their former state at approximately a mean of 4.2 months after cessation of NBUVB exposure in both study groups. However, dermoscopic changes remained in some MN. In addition, dermoscopic changes emerged 3-6 months after the end therapy in some MN that did not show any dermoscopic changes at the end of therapy. Those dermoscopic changes can be due to late-onset or persistent effects of NBUVB but can also be related to the natural evolution of MN, independent from NBUVB, as claimed by Dobrosavljevic et al. Long-term follow up studies may clarify this condition [18].

**Conclusion**

In conclusion, NBUVB treatment cause various dermoscopic changes in MN; some of these changes can be prevented with opaque tape. SSc in combination with opaque tape helps in preventing the development of dermoscopic changes in MN, including size decrease and structure loss.

**Acknowledgments**

This study was financially supported by grant number 2015TPF011 from the Scientific Research Projects Foundation of Pamukkale University. We thank Hande Şenol, Lecturer, for her help and comments in statistical analyses.

**References**

1. Sokolova A, Lee A, D Smith S. The safety and efficacy of narrow band ultraviolet B treatment in dermatology: a review. *J Am Acad Dermatol*. 2015;61(6):118.
2. Sebode C, Lehmann J, Emmert S. Photocarcinogenesis and Skin Cancer Prevention Strategies. *Anticancer Res*. 2016;36(3):1371-1378.
3. Hofmann-Wellenhof R, Soyer HP, et al. Ultraviolet radiation of melanocytic nevi: a dermoscopic study. *Arch Dermatol*. 1998;134(7):845-850.
4. Stanganelli I, Rafanelli S, Bucchi L. Seasonal prevalence of digital epiluminescence microscopy patterns in acquired melanocytic nevi. *J Am Acad Dermatol*. 1996;34(3):460-464.
5. Hofmann-Wellenhof R, Wolf P, Smolle J, Reimann-Weber A, Soyer HP, Kerl H. Influence of UVB therapy on dermoscopic features of acquired melanocytic nevi. *J Am Acad Dermatol*. 1997;37(4):559-563.
6. Manganoni AM, Rossi MT, Sala R, et al. Dermoscopic, histological and immunohistochemical evaluation of cancerous features in acquired melanocytic nevi that have been repeatedly exposed to UVA or UVB. *Exp Dermatol*. 2011;21(2):86-90.
7. Ghani-Nejad H, Hallaj Z, Damavandi MR, et al. Dermoscopic changes of melanocytic nevi after psoralen-ultraviolet A and narrow-band ultraviolet B phototherapy. *Indian J Dermatol*. 2016;61(1):118.
8. Kilinc Karaaslan I, TEBAN L, DAWID M, TANEW A, KITTLER H. Changes in the dermoscopic appearance of melanocytic naevi after photochemotherapy or narrowband ultraviolet B phototherapy. *J Eur Acad Dermatol Venereol*. 2007;21(4):526-531.
9. Akdeniz N. Fototerapinin yan etkileri ve kontrendikasyonları. In: Elçin G, Karadağ AS, Yılmaz E, eds. Fotodermatoloji. 1st ed. Istanbul: Galenos Yayınevi. 2015:315-333.

10. Grichnik JM, Rhodes AR, Sober AJ. Benign neoplasias and hyperplasias of melanocytes. In: Wolff K, Goldsmith LA, Katz SL, Gilchrest BA, Paller AS, Leffell DJ, eds. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York: McGraw-Hill. 2008:1099-1122.

11. Gallagher RP, Rivers JK, Lee TK, Bajdik CD, McLean DI, Goldman AJ. Broad-spectrum sunscreen use and the development of new nevi in white children: a randomized controlled trial. JAMA. 2000;283(22):2955-2960.

12. Menzies SW, Greenoak GE, Abeywardana CM, Crotty KA, O’Neill ME. UV light from 290 to 325 nm, but not broad-band UVA or visible light augments the formation of melanocytic nevi in a guinea-pig model for human nevi. J Invest Dermatol. 2004;123(2):354-360.

13. Dulon M, Weichenthal M, Blettner M, et al. Sun exposure and number of nevi in 5- to 6-year-old European children. J Clin Epidemiol. 2002;55(11):1075-1081.

14. Wachsmuth RC, Turner F, Barrett JH, et al. The effect of sun exposure in determining nevus density in UK adolescent twins. J Invest Dermatol. 2005;124(1):56-62.

15. Harrison SL, MacLennan R, Buettner PG. Sun exposure and the incidence of melanocytic nevi in young Australian children. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2318-2324.

16. Lin CY, Oakley A, Rademaker M, Hill S, Yung A. Effect of narrowband ultraviolet B phototherapy on melanocytic naevi. Br J Dermatol. 2013;168(4):815-819.

17. Karaca F, Öztas M, Gürer MA. Effects of narrow band UVB, UVA1 and PUVA treatments on dermoscopic features of melanocytic nevi. Turkderm. 2014;48(1):26-30.

18. Dobrosavljevic D, Brasanac D, Apostolovic M, Medenica L. Changes in common melanocytic naevi after intense sun exposure: digital dermoscopic study with a 1-year follow-up. Clin Exp Dermatol. 2009;34(6):672-678.

19. Terushkin V, Scope A, Hofmann-Wellenhof R, Marghoob A. Disappearance of Melanocytic Nevi. In: Marghoob A, ed. Nevogenesis. Verlag Berlin Heidelberg: Springer. 2012:145-153.

20. Kintler H. Evolution of nevi. In: Marghoob A, ed. Nevogenesis. Verlag Berlin Heidelberg: Springer. 2012:43-47.